Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-r... Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0168 | -43.1876606684 | 0.0389 | 0.0389 | 0.0221 | 21777 | 0.0389 | DR |
| 4 | -0.0469 | -67.9710144928 | 0.069 | 0.069 | 0.0152 | 80232 | 0.02734189 | DR |
| 12 | 0.0026 | 13.3333333333 | 0.0195 | 0.069 | 0.0152 | 26361 | 0.02711553 | DR |
| 26 | 0.004 | 22.0994475138 | 0.0181 | 0.0975 | 0.0017 | 21897 | 0.02722569 | DR |
| 52 | -0.9879 | -97.8118811881 | 1.01 | 3.17 | 0.0017 | 30797 | 0.04873601 | DR |
| 156 | -0.9879 | -97.8118811881 | 1.01 | 3.17 | 0.0017 | 30797 | 0.04873601 | DR |
| 260 | -0.9879 | -97.8118811881 | 1.01 | 3.17 | 0.0017 | 30797 | 0.04873601 | DR |
splintered sunlight
7月前
splintered sunlight
7月前
makinezmoney
5年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。